Dear Dr. Renukaprasad A R,  Do you support the use of empagliflozin for heart failure patients, irrespective of their diabetic status? Recent studies demonstrate that empagliflozin reduces the risk of hospitalization and death among heart failure patients. However, the proper use of drugs is essential for better treatment outcomes.
Check out this booklet, "HOPE", with seven chapters covering the basic aspects of empagliflozin along with its utility in various fields ranging from endocrinology to cardiology and nephrology. Highlights:- Common ground for cardiovascular, kidney, and metabolic effects
- Three levels of disease modification with SGLT2-i
- SGLT2-i as evolving Standards of CARE (CVD, adiposity, renal disease, endocrinology)
- The interlinking of mechanisms and possible risks
CVD: Cardiovascular disease; SGLT2-i: Sodium-glucose cotransport-2 inhibitor | .jpg)
No comments:
Post a Comment